UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome

Blood, 2018-09, Vol.132 (13), p.1365-1371

2018

Volltextzugriff (PDF)

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges

Journal of the American Heart Association, 2020-07, Vol.9 (13), p.e017559

2020

Volltextzugriff (PDF)

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-11, Vol.326 (17), p.1703

2021

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.628-636

2016

Volltextzugriff (PDF)

Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2018-09, Vol.16 (9), p.1891-1894

2018

Volltextzugriff (PDF)

2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Thrombosis and haemostasis, 2021-08, Vol.121 (8), p.1008-1020

2021

Volltextzugriff (PDF)

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis

Blood, 2020-09, Vol.136 (12), p.1433-1441

2020

Volltextzugriff (PDF)

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.2119-2126

2015

Volltextzugriff (PDF)

Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation

The New England journal of medicine, 2020-10, Vol.383 (18), p.1735-1745

2020

Volltextzugriff (PDF)

Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents

Circulation (New York, N.Y.), 2016-07, Vol.134 (3), p.248-261

2016

Volltextzugriff (PDF)

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

The Lancet (British edition), 2015-06, Vol.385 (9984), p.2288-2295

2015

Volltextzugriff (PDF)

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

Circulation (New York, N.Y.), 2015-01, Vol.131 (1), p.82-90

2015

Volltextzugriff (PDF)

Pharmacokinetics of Edoxaban 15 mg in Very Elderly Patients with Nonvalvular Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Study

Thrombosis and haemostasis, 2024-09, Vol.124 (9), p.874-882

2024

Volltextzugriff (PDF)

Treatment of bleeding complications in patients on anticoagulant therapy

Blood, 2019-01, Vol.133 (5), p.425-435

2019

Volltextzugriff (PDF)

Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus

Journal of the American College of Cardiology, 2020-04, Vol.75 (14), p.1676-1685

2020

Volltextzugriff (PDF)

Dose-Finding Study of Rivaroxaban in Hemodialysis Patients

American journal of kidney diseases, 2015-07, Vol.66 (1), p.91-98

2015

Volltextzugriff (PDF)

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2019-10, Vol.17 (10), p.1772-1778

2019

Volltextzugriff (PDF)

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Circulation (New York, N.Y.), 2017-03, Vol.135 (13), p.1273-1275

2017

Volltextzugriff (PDF)

Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review

JAMA : the journal of the American Medical Association, 2020-11, Vol.324 (17), p.1765

2020

Volltextzugriff (PDF)

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

European heart journal, 2015-05, Vol.36 (20), p.1264-1272

2015

Volltextzugriff (PDF)

Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages

Journal of thrombosis and haemostasis, 2020-07, Vol.18 (7), p.1637-1647

2020

Volltextzugriff (PDF)

Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis

Pharmacotherapy, 2024-05, Vol.44 (5), p.394-408

2024

Volltextzugriff (PDF)

Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment

Cardiovascular research, 2021-07, Vol.117 (9), p.2030-2044

2021

Volltextzugriff (PDF)

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis

Thrombosis and haemostasis, 2015-07, Vol.113 (4), p.719-727

2015

Volltextzugriff (PDF)

1 – 25 von 1.255

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.146)
Mit Volltextzugriff
(851)

Publikationsform

Sprache

10 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(1.203)
Science & Technology
(1.057)
Life Sciences & Biomedicine
(1.045)
Anticoagulants - Adverse Effects
(600)
Factor Xa Inhibitors - Adverse Effects
(535)
Factor Xa Inhibitors
(483)
Cardiovascular System & Cardiology
(477)
Hemorrhage - Chemically Induced
(432)
Anticoagulants - Therapeutic Use
(376)
Administration, Oral
(360)
Anticoagulants
(356)
Rivaroxaban
(317)
Male
(306)
Factor Xa Inhibitors - Therapeutic Use
(302)
Anticoagulants - Administration & Dosage
(285)
Peripheral Vascular Disease
(284)
Female
(274)
Hematology
(274)
Cardiac & Cardiovascular Systems
(261)
Pharmacology & Pharmacy
(258)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH

2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

Pharmacokinetics of Edoxaban 15 mg in Very Elderly Patients with Nonvalvular Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Study

Treatment of bleeding complications in patients on anticoagulant therapy

Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus

Dose-Finding Study of Rivaroxaban in Hemodialysis Patients

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages

Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis

Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis

Aktive Filter

Suchergebnisse filtern